



Date: 10.08.2022

### Certification of Collaboration for Research

This is to acknowledge that Prof. (Dr.) Satyanarayan Pattnaik, Department of Pharmaceutics of Talla Padmavathi College of Pharmacy, Warangal, Telangana, India has been in active collaboration support since 2021 with Prof. (Dr.) Santanu Chakraborty, Divisional In-charge of Pharmaceutics Division, Dr. B. C. Roy College of Pharmacy & Allied Health Sciences, Durgapur, WB, India. In this collaboration, we contributed to mentoring the design of various research proposals, experiments, instruments and many more.

We have shared our ideas and views in writing of various review articles, book chapters and research articles. We have actively participated in achieving Indian Design Patents as well as UK Design Patent. Apart from this, we also jointly work on various formulation design and development. We also published various research as well as review papers in various international reputed journals.

We are hopeful to carry this collaborative research in near future also.

Name: Prof. (Dr.) Santanu Chakraborty

Designation: Professor and Divisional In-Charge of Pharmaceutics Dr. B. C. Roy College of Pharmacy & Allied Health Sciences

Durgapur, WB, India

J. Chakraharty.

Signature with Seal (1st Party)

Date: 10-08-2022

Name: Prof. (Dr.) Satyanarayan Pattnaik

Designation: Professor, Department of Pharmaceutics Talla Padmavathi College of Pharmacy,

Warangal, Telangana, India.

Spaltrain

Signature with Seal (2<sup>nd</sup> Party):

Date: 10-08-2022





Prof. (Dr.) Saroh/Mumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS Durgapur, West Bengal-713206

### REVIEW ARTICLE



# A Critical Appraisal of Lipid Nanoparticles Deployed in Cancer Pharmacotherapy



Santanu Chakraborty<sup>1</sup>, Manami Dhibar<sup>1</sup>, Aliviya Das<sup>2</sup>, Kalpana Swain<sup>3</sup> and Satyanarayan Pattnaik<sup>3</sup>.\*

<sup>1</sup>Formulation Development Research Unit, Department of Pharmaceutics, Dr. B. C. Roy College of Pharmacy and AHS, Durgapur-713206, West Bengal, India; <sup>2</sup>Calcutta Institute of Pharmaceutical Technology & AHS, Uluberia, Howrah, West Bengal, India; <sup>3</sup>Division of Advanced Drug Delivery, Talla Padmavathi College of Pharmacy, Warangal, India

### ARTICLE HISTORY

Received: November 07, 2022 Revised; June 16, 2023 Accepted: June 21, 2023

DOI: 10.2174/2667387817666230726140745



Abstract: Treatment modalities of various cancers and the delivery strategies of anticancer agents have evolved significantly in the recent past. The severity and fatality of the disease and hurdles to the effective delivery of therapeutic agents have drawn the attention of researchers across the world for proposing novel and effective drug delivery strategies for anticancer therapeutics. Attempts have been made to propose solutions to the diverse limitations like poor pharmacokinetics and higher systemic toxicities of the traditional delivery of anticancer agents. Nanotechnology-based drug delivery systems including lipid-based nanocarriers have demonstrated significant efficiency in this scenario. The review critically assessed the different types of lipid ganocarrier systems for the effective and optimal delivery of anticancer therapeutic agents. The diverse synthesis approaches are discussed for the laboratory scale and commercial development of different categories of lipid nanocarriers. Further, their application in anticancer drug delivery is illustrated in detail followed by a critical appraisal of their safety and toxicity.

Keywords: Lipid-based nanocarriers, nanomedicine, cancers, nanotoxicity, liposomes, solid lipid nanoparticles.

### 1. INTRODUCTION

ECONT AMERICA IN DING Delivery & Formulation

Cancer is the world's second-biggest cause of death and treating it remains a serious problem as the number of cases rises. Patients with cancer are treated with a variety of methods, including surgery, chemotherapy, radiotherapy, and immunotherapy. Chemotherapy, on the other hand, may be the only way to improve survival odds once cancer has spread and become metastatic [1]. Except for breast cancer, which is treated with hormone treatment or immunotherapy; cytotoxic drugs are still the most common type of cancer chemotherapy. Anticancer drugs are usually cytotoxic agents which treat cancer by acting against the cancerous cells. These drugs preferentially target cancer cells because they frequently undergo fast growth and proliferation [2]. Despite decades of research, there are still significant unmet medical requirements in cancer detection and treatment, However, there are a large number of potentially effective therapeutic agents (both biopharmaceutical and smallmolecule drug-related) that are either too large highly charged, unstable, and not too soluble to reach cancer target cells without the use of delivery "vehicles." [3]. The last few decades have witnessed a significant contribution of molecular biology in understanding cancer biology in a better

manner. This has paved the way for the development of therapeutic compounds that target the source of the problem: the molecular and cellular processes that lead to disease development. Unfortunately, many drug molecules are therapeutically ineffective due to diverse reasons including their poor aqueous solubility, and hence, require specialized delivery vehicles. In some cases, medications are unable to pass through cell membranes, resulting in insufficient concentrations at the target region. To overcome this, substantial pharmacological doses are required, resulting in side effects [4, 5]. To overcome this, Cancer nanotechnology has emerged as a cancer treatment method for anticancer medication delivery [6]. Nanomedicine has evolved as a viable technique not only for enhancing drug therapeutic index but also for overcoming biological obstacles over the last 20 years. Nanoparticles as drug delivery systems are made up of inorganic or organic components with diameters ranging from 1 to 1000 nanometres [7]. They can prevent chemotherapeutic drugs from degrading too quickly, extending their biological half-life. The first nanomedicines to be commercialized in cancer therapy were liposomes for parenteral delivery [8-11]. Polymeric micelles, or nanoscale supramolecular constructions made out of amphiphilic block copolymers, are proving to be effective drug delivery vehicles for lipophilic drugs [12]. Liposomes, which consist of one or more lipid bilayers encapsulating an aqueous core, are now the most popular nanoparticle Hrug delivery vehi-

\*Address correspondence to this author at the Division of Advanced Drug Delivery, Talla Padmavathi College of Pharmacy, Warangal, India; Tcl: +91-7386752616; E-mail: drsatyapharma@gmail.com

College of Anguaria

2667-3886/23 \$65,00+.00


O 2023 Bentham Science Publishers

Prof. (Dr.) Saila Rumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS Durgapur, West Bengal 713208



# ESSENTIAL OLLO

Extraction Methods and Applications



# **Essential Oils**



Prof. (Dr.) Sahir kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS Durgapur, West Bengal-713206

### Scrivener Publishing 100 Cummings Center, Suite 541J Beverly, MA 01915-6106

Publishers at Scrivener

Martin Scrivener (martin@scrivenerpublishing.com)

Phillip Carmical (pcarmical@scrivenerpublishing.com)



Prof. (Dr.) Samir Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS Durgapur, West Bengal-713206 10 1002 9781118S20614 finding. Dwinkoded from https://onlineshbraty.wiley.com/dxi10 1002 9781119829614 finding. Wiley Online Library on [10.07/2023] See the Terms and Conditions (https://onlinelibrary.wiley.com/darms-and-conditions) on Wiley Online Library for rules of once OA articles are govern-

# **Essential Oils**

## **Extraction Methods and Applications**

# Edited by **Inamuddin**



Prof. (Dr.) Samir Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS Durgapur, West Bengal-713206



WILEY

This edition first published 2023 by John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA and Scrivener Publishing LLC, 100 Cummings Center, Suite 541J, Beverly, MA 01915, USA

© 2023 Scrivener Publishing LLC

For more information about Scrivener publications please visit www.scrivenerpublishing.com.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.

### Wiley Global Headquarters

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www. wiley.com.

Limit of Liability/Disclaimer of Warranty

While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchant-ability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials, or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read.

### Library of Congress Cataloging-in-Publication Data

ISBN 9781119829355

Front cover image: Pixabay.com Cover design by Russell Richardson

Set in size of 11pt and Minion Pro by Manile Type setting Company, Makati, Philippines

Printed in the USA

10 9 8 7 6 5 4 3 2 1



Prof. (Dr.) Saihir Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Rey College of Pharmacy & AHS Durgapur, West Bengal-713206

# Contents

10.1002/STR1119529014 finalths. Downloaded from https://cohinelibrary.wiley.com/doi/10.1002/9781119529014 finalter, Wiley Online Library on [10/07/2033] See the Terms and Conditions (https://cohinelibrary.wiley.com/doi/10.1002/9781119529014 finalter, Wiley Online Library on [10/07/2033] See the Terms and Conditions (https://cohinelibrary.wiley.com/doi/10.1002/9781119529014 finalter, Wiley Online Library for rules of use; GA stables are generated by the applicable Contained Library on [10/07/2033] See the Terms and Conditions (https://cohinelibrary.wiley.com/doi/10.1002/9781119529014 finalter).

Components for Antiviral Activities   1	Pre	eface				xxvii		
1.1 Introduction 1.2 General Chemical Properties and Bioactivity 2 1.3 Antiviral Mechanisms 3 1.3.1 Time of Addition Assay 1.3.1.1 Pretreatment of Host Cells 1.3.1.2 Pretreatment of Wirions 1.3.1.3 Co-Treatment of Host/Cultured Cells and Virions During Virus Inoculation 5 1.3.1.4 Post-Entry Treatment 6 1.3.2 Thermal Shift Assays 6 1.3.2.1 Viral Attachment Assay 1.3.2.2 Viral Fusion Assay (Entry Assay) 6 1.3.3 Morphological Study 1.3.4 Protein Inhibition 1.3.5 Other Metabolic Anti-Viral Mechanisms 9 1.4 Assessment of Antiviral Activities via In Vitro Assays 1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay) 1.4.2 In Vitro Activities on Different Viruses 1.4.2.1 Human Herpes Virus 1.4.2.2 Influenza Virus 1.4.2.3 Non-Enveloped Viruses 1.4.2.4 Other Viruses 1.5 Activities of Essential Oils in Relation to Their Bioactive Components 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 1.7.3 West Nile Virus 1.7.4 Influenza Virus 1.7.5 Influenza Virus 1.7.6 (Dr.) Schilf Kumar Samanté M. Pharm., Ph.D. (J. U.) Principal Ch. B. C. Roy Collègee of Pharmany & AHS  Dr. B. C. Roy Collègee of Pharmany & AHS  Dr. B. C. Roy Collègee of Pharmany & AHS  Dr. B. C. Roy Collègee of Pharmany & AHS  Dr. B. C. Roy Collègee of Pharmany & AHS  Dr. B. C. Roy Collègee of Pharmany & AHS  Dr. B. C. Roy Collègee of Pharmany & AHS  Dr. B. C. Roy Collègee of Pharmany & AHS  Dr. B. C. Roy Collègee of Pharmany & AHS	1	Components for Antiviral Activities Kunal Sharma, Vivek Mishra, Kumar Rakesh Ranjan, Nisha Yadav						
1.2 General Chemical Properties and Bioactivity  2.1.3 Antiviral Mechanisms  1.3.1 Time of Addition Assay  1.3.1.1 Pretreatment of Host Cells  1.3.1.2 Pretreatment of Virions  1.3.1.3 Co-Treatment of Host/Cultured Cells and Virions  During Virus Inoculation  1.3.1.4 Post-Entry Treatment  1.3.2 Thermal Shift Assays  1.3.2.1 Viral Attachment Assay  1.3.2.2 Viral Fusion Assay (Entry Assay)  1.3.3 Morphological Study  1.3.4 Protein Inhibition  1.3.5 Other Metabolic Anti-Viral Mechanisms  1.4 Assessment of Antiviral Activities via In Vitro Assays  1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay)  1.4.2 In Vitro Activities on Different Viruses  1.4.2.1 Human Herpes Virus  1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.4.2.4 Other Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.3 West Nile Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Capped Planaray & Aris  1.7.9 Influenza Virus  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.6 Capped Planaray & Aris  1.7.7 Pinicapal  1.7.8 Capped Planaray & Aris  1.7.9 Pinicapal  1.7.9 Capped Planaray & Aris  1.7.9 Capped Planaray & Aris  1.7.1 Capped Planaray & Aris  1.7.2 Capped Planaray & Aris  1.7.3 Capped Planaray & Aris  1.8 Capped Capped Planaray & Aris  1.9 Pinicapal  1.10 Capped Planaray & Aris  1.11 Capped Planaray & Aris  1.12 Planaray & Aris  1.13 Capped Planaray & Aris  1.14 Capped Planaray & Aris  1.15 Capped Capped Planaray & Aris  1.15 Capped Planaray & Aris  1.16 Capped Planaray & Aris  1.17 Capped Planaray & Aris  1.18 Capped Capped Planaray & Aris						1		
1.3 Antiviral Mechanisms 1.3.1 Time of Addition Assay 1.3.1.1 Pretreatment of Host Cells 1.3.1.2 Pretreatment of Virions 1.3.1.3 Co-Treatment of Host/Cultured Cells and Virions During Virus Inoculation 1.3.1.4 Post-Entry Treatment 1.3.2 Thermal Shift Assays 1.3.2.1 Viral Attachment Assay 1.3.2.2 Viral Fusion Assay (Entry Assay) 1.3.3 Morphological Study 1.3.4 Protein Inhibition 1.3.5 Other Metabolic Anti-Viral Mechanisms 1.4 Assessment of Antiviral Activities via In Vitro Assays 1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay) 1.4.2 In Vitro Activities on Different Viruses 1.4.2.1 Human Herpes Virus 1.4.2.2 Influenza Virus 1.4.2.3 Non-Enveloped Viruses 1.4.2.4 Other Viruses 1.5 Activities of Essential Oils in Relation to Their Bioactive Components 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 1.7.3 West Nile Virus 1.7.4 Influenza Virus 1.7.5 Influenza Virus 1.7.5 Influenza Virus 1.7.6 (Dr.) Sainf Kumar Samante M. Pharm., Ph.D. (J.U.) 1.7 Principal 1.7 Influenza Virus 1.7 M. Pharm., Ph.D. (J.U.) 1.7 Principal 1.7 Influenza Virus 1.7 M. Pharm., Ph.D. (J.U.) 1.7 Principal 1.7 Influenza Virus 1.7 M. Pharm., Ph.D. (J.U.) 1.7 Principal 1.7 Influenza Virus 1.7 M. Pharm., Ph.D. (J.U.) 1.7 Principal 1.7 Influenza Virus 1.7 M. Pharm., Ph.D. (J.U.) 1.7 Principal 1.7 Influenza Virus 1.7 M. Pharm., Ph.D. (J.U.) 1.7 Principal 1.7 Influenza Virus 1.7 M. Pharm., Ph.D. (J.U.) 1.7 Principal 1.7 Influenza Virus 1.7 Respect to the Available Antivirals					cal Properties and Rioactivity			
1.3.1 Time of Addition Assay  1.3.1.1 Pretreatment of Host Cells  1.3.1.2 Pretreatment of Virions  1.3.1.3 Co-Treatment of Host/Cultured Cells and Virions  During Virus Inoculation  1.3.1.4 Post-Entry Treatment  1.3.2 Thermal Shift Assays  1.3.2.1 Viral Attachment Assay  1.3.2.2 Viral Fusion Assay (Entry Assay)  1.3.3 Morphological Study  1.3.4 Protein Inhibition  1.3.5 Other Metabolic Anti-Viral Mechanisms  1.4 Assessment of Antiviral Activities via In Vitro Assays  1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay)  1.4.2 In Vitro Activities on Different Viruses  1.4.2.1 Human Herpes Virus  1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7 In Vivo Studies of Essential Oils for its Antiviral Effect  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.3 West Nile Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.6 Activities In-Respect to the Available Antivirals  1.7.7 Influenza Virus  1.7.8 Influenza Virus  1.7.9 Influenza Virus  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.3 West Nile Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.6 Apy College of Pharmary & AHS  1.7.7 Influenza Virus  1.7.8 Apy College of Pharmary & AHS								
1.3.1.1 Pretreatment of Host Cells 1.3.1.2 Pretreatment of Virions 1.3.1.3 Co-Treatment of Host/Cultured Cells and Virions During Virus Inoculation 5 1.3.1.4 Post-Entry Treatment 6 1.3.2 Thermal Shift Assays 6 1.3.2.1 Viral Attachment Assay 6 1.3.2.2 Viral Fusion Assay (Entry Assay) 6 1.3.3 Morphological Study 6 1.3.4 Protein Inhibition 7 1.3.5 Other Metabolic Anti-Viral Mechanisms 9 1.4 Assessment of Antiviral Activities via In Vitro Assays 9 1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay) 1.4.2 In Vitro Activities on Different Viruses 1.4.2.1 Human Herpes Virus 1.4.2.2 Influenza Virus 1.4.2.3 Non-Enveloped Viruses 1.4.2.4 Other Viruses 1.5 Activities of Essential Oils in Relation to Their Bioactive Components 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 1.8 Prof. (Dr.) Sahif Kumar Samante M. Pharm., Ph.D (J.U.) 1.9 Principal Dr. B. C. Roy Colleged Pharmany & AHS  Dr. B. C. Roy Colleged Pharmany & AHS		1.5						
1.3.1.2 Pretreatment of Virions 1.3.1.3 Co-Treatment of Host/Cultured Cells and Virions During Virus Inoculation 1.3.1.4 Post-Entry Treatment 6 1.3.2 Thermal Shift Assays 6 1.3.2.1 Viral Attachment Assay 1.3.2.2 Viral Fusion Assay (Entry Assay) 6 1.3.3 Morphological Study 7 1.3.5 Other Metabolic Anti-Viral Mechanisms 9 1.4 Assessment of Antiviral Activities via In Vitro Assays 1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay) 1.4.2 In Vitro Activities on Different Viruses 1.4.2.1 Human Herpes Virus 1.4.2.2 Influenza Virus 1.4.2.3 Non-Enveloped Viruses 1.5 Activities of Essential Oils in Relation to Their Bioactive Components 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 20 21 21 22 24 24 25 Prof. (Dr.) Sahif Kumar Samants 26 M. Pharm., Ph.D (J.U.) 27 28 29 20 21 20 21 21 21 21 22 22 21 21 22 21 21 22 22			1.5.1					
1.3.1.3 Co-Treatment of Host/Cultured Cells and Virions During Virus Inoculation  1.3.1.4 Post-Entry Treatment  6 1.3.2 Thermal Shift Assays 6 1.3.2.1 Viral Attachment Assay 6 1.3.2.2 Viral Fusion Assay (Entry Assay) 6 1.3.3 Morphological Study 6 1.3.4 Protein Inhibition 7 1.3.5 Other Metabolic Anti-Viral Mechanisms 9 1.4 Assessment of Antiviral Activities via In Vitro Assays 1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay) 9 1.4.2 In Vitro Activities on Different Viruses 1.4.2.1 Human Herpes Virus 1.4.2.2 Influenza Virus 1.4.2.3 Non-Enveloped Viruses 1.4.2.4 Other Viruses 1.5 Activities of Essential Oils in Relation to Their Bioactive Components 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 1.7.3 West Nile Virus 1.7.4 Principal 1.7.5 Influenza Virus 1.7.5 Influenza Virus 1.7.6 Influenza Virus 1.7.7 West Nile Virus 1.7.8 Principal 1.7.9 Influenza Virus 1.7.9 Influenza Virus 1.7.1 Principal 1.7.1 Principal 1.7.2 Influenza Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 1.7.3 West Nile Virus 1.7.4 Principal 1.7.5 Influenza Virus 1.7.5 Principal 1.7.6 C. Roy College of Pharmacy & AHS								
During Virus Inoculation  1.3.1.4 Post-Entry Treatment  6  1.3.2 Thermal Shift Assays  6  1.3.2.1 Viral Attachment Assay  6  1.3.2.2 Viral Fusion Assay (Entry Assay)  6  1.3.3 Morphological Study  1.3.4 Protein Inhibition  7  1.3.5 Other Metabolic Anti-Viral Mechanisms  9  1.4 Assessment of Antiviral Activities via In Vitro Assays  1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay)  1.4.2 In Vitro Activities on Different Viruses  1.4.2.1 Human Herpes Virus  1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7 In Vivo Studies of Essential Oils for its Antiviral Effect  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.3 West Nile Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Influenza Virus  1.7.9 Influenza Virus  1.7.1 Influenza Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Influenza Virus  1.7.9 Influenza Virus  1.7.1 Influenza Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.3 Influenza Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.6 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Influenza Virus  1.7.9 Influenza Virus  1.7.1 Influenza Virus  1.7.2 Influenza Virus  1.7.3 Influenza Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.6 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Influenza Virus  1.7.9 Influenza Virus  1.7.1 Influenza Virus  1.7.2 Influenza Virus  1.7.3 Influenza Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.6 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Influenza Virus  1.7.9 Influenza Virus  1.7.1 Influenza Virus  1.7.2 Influenza Virus  1.7.3 Influenza Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.6 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Influenza Virus  1.7.9 Influenza Virus  1.7.1 Influenza Virus  1.7.2 Influenza Virus								
1.3.1.4 Post-Entry Treatment  1.3.2 Thermal Shift Assays  1.3.2.1 Viral Attachment Assay  1.3.2.2 Viral Fusion Assay (Entry Assay)  1.3.3 Morphological Study  1.3.4 Protein Inhibition  1.3.5 Other Metabolic Anti-Viral Mechanisms  1.4 Assessment of Antiviral Activities via In Vitro Assays  1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay)  1.4.2 In Vitro Activities on Different Viruses  1.4.2.1 Human Herpes Virus  1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7 In Vivo Studies of Essential Oils for its Antiviral Effect  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  20  Prof. (Dr.) Samir Kumar Samanta M. Pharm., Ph.D (J.U.)  Principal  1.7.3 Ph.D (J.U.)  Principal  1.7.4 E. C. Roy College of Pharmacy & AMS				1.5.1.0		5		
1.3.2 Thermal Shift Assays  1.3.2.1 Viral Attachment Assay  1.3.2.2 Viral Fusion Assay (Entry Assay)  6  1.3.3 Morphological Study  1.3.4 Protein Inhibition  7  1.3.5 Other Metabolic Anti-Viral Mechanisms  9  1.4 Assessment of Antiviral Activities via In Vitro Assays  1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay)  1.4.2 In Vitro Activities on Different Viruses  1.4.2.1 Human Herpes Virus  1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.4.2.4 Other Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7 In Vivo Studies of Essential Oils for its Antiviral Effect  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.3 West Nile Virus  1.8 Prof. (Dr.) Sahili Kumar Samanta M. Pharm., Ph.D (J.U.)  1.9 Principal  1.1 Dr. B. C. Roy College of Pharmacy & AHS				1.3.1.4		6		
1.3.2.1 Viral Attachment Assay 1.3.2.2 Viral Fusion Assay (Entry Assay) 6 1.3.3 Morphological Study 6 1.3.4 Protein Inhibition 7 1.3.5 Other Metabolic Anti-Viral Mechanisms 9 1.4 Assessment of Antiviral Activities via In Vitro Assays 1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay) 9 1.4.2 In Vitro Activities on Different Viruses 12 1.4.2.1 Human Herpes Virus 12 1.4.2.2 Influenza Virus 13 1.4.2.3 Non-Enveloped Viruses 15 1.4.2.4 Other Viruses 16 1.5 Activities of Essential Oils in Relation to Their Bioactive Components 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 1.7.3 West Nile Virus 1.7.4 Principal 1.7.5 Influenza Virus 1.7.6 Prof. (Dr.) Stalif Kumar Samanta M. Pharm., Ph.D. (J.U.) 1.7 Principal Dr. 8, C. Roy College of Pharmacy & AHS			1 3.2			6		
1.3.2.2 Viral Fusion Assay (Entry Assay)  1.3.3 Morphological Study  1.3.4 Protein Inhibition  1.3.5 Other Metabolic Anti-Viral Mechanisms  9  1.4 Assessment of Antiviral Activities via In Vitro Assays  1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay)  9  1.4.2 In Vitro Activities on Different Viruses  1.4.2.1 Human Herpes Virus  1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.4.2.4 Other Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7 In Vivo Studies of Essential Oils for its Antiviral Effect  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  20  21  22  23  24  25  26  27  26  27  27  28  28  28  29  20  20  21  21  22  23  24  26  27  26  27  28  28  29  20  20  20  21  21  22  23  24  26  27  28  29  20  20  20  21  21  22  23  24  26  27  28  28  29  20  20  20  21  21  21  22  23  24  26  27  28  29  20  20  20  21  21  22  23  24  26  27  28  28  29  20  20  20  21  21  22  23  24  26  27  28  28  29  20  20  21  21  22  23  24  26  27  28  28  29  20  20  20  21  21  22  22  23  24  26  27  28  28  29  20  20  20  20  20  20  20  20  20			1.5.2			6		
1.3.3 Morphological Study 1.3.4 Protein Inhibition 1.3.5 Other Metabolic Anti-Viral Mechanisms 9 1.4 Assessment of Antiviral Activities via In Vitro Assays 9 1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay) 9 1.4.2 In Vitro Activities on Different Viruses 12 1.4.2.1 Human Herpes Virus 12 1.4.2.2 Influenza Virus 13 1.4.2.3 Non-Enveloped Viruses 14 1.4.2.4 Other Viruses 15 1.5 Activities of Essential Oils in Relation to Their Bioactive Components 16 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 17 18 19 10 10 10 10 10 11 11 11 11 11 11 11 11						6		
1.3.4 Protein Inhibition 1.3.5 Other Metabolic Anti-Viral Mechanisms 9 1.4 Assessment of Antiviral Activities via In Vitro Assays 9 1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay) 9 1.4.2 In Vitro Activities on Different Viruses 1.4.2.1 Human Herpes Virus 1.4.2.2 Influenza Virus 1.4.2.3 Non-Enveloped Viruses 1.4.2.4 Other Viruses 1.5 Activities of Essential Oils in Relation to Their Bioactive Components 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 1.7.3 West Nile Virus 1.7.4 Influenza Virus 1.7.5 Influenza Virus 1.7.6 Influenza Virus 1.7.7 Influenza Virus 1.7.8 Components 1.7.9 Influenza Virus 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 Prof. (Dr.) Sould Kumar Samanta M. Pharm., Ph.D. (J.U.) 1.7 Principal			1.3.3					
1.3.5 Other Metabolic Anti-Viral Mechanisms  1.4 Assessment of Antiviral Activities via In Vitro Assays  1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay)  1.4.2 In Vitro Activities on Different Viruses  1.4.2.1 Human Herpes Virus  1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.4.2.4 Other Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7 In Vivo Studies of Essential Oils for its Antiviral Effect  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.6 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Cipter Simplex Virus  1.7.9 Influenza Virus  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.6 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Cipter Sanit Kumar Samanta M. Pharm., Ph.D (J.U.)  1.7 Principal Dr. B. C. Roy College of Pharmacy & AHS								
1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay)  1.4.2 In Vitro Activities on Different Viruses  1.4.2.1 Human Herpes Virus  1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.4.2.4 Other Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7 In Vivo Studies of Essential Oils for its Antiviral Effect  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.3 West Nile Virus  1.8 Prof. (Dr.) Sami Kumar Samanta M. Pharm., Ph.D (J.U.)  Principal  Dr. B. C. Rey College of Pharmacy & AHS		•						
1.4.1 Determination of Cytotoxicity (Cytopathogenic Reduction Assay)  1.4.2 In Vitro Activities on Different Viruses  1.4.2.1 Human Herpes Virus  1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.4.2.4 Other Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7 In Vivo Studies of Essential Oils for its Antiviral Effect  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.4 Influenza Virus  1.7.5 Activities In-Respect to the Available Antivirals  1.7.6 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Influenza Virus  1.7.9 Influenza Virus  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.4 Influenza Virus  1.7.5 Influenza Virus  1.7.6 Influenza Virus  1.7.7 Influenza Virus  1.7.8 Influenza Virus  1.7.9 Influenza Virus  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus		1.4	Asses	sment of A	Antiviral Activities via In Vitro Assays			
1.4.2 In Vitro Activities on Different Viruses  1.4.2.1 Human Herpes Virus  1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.4.2.4 Other Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7 In Vivo Studies of Essential Oils for its Antiviral Effect  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  1.7.4 Vivo Studies of Essential Oils for its Antiviral Effect  1.7.5 Influenza Virus  1.7.6 Principal  1.7.7 Ph.D (J.U.)  1.7 Principal			1.4.1	Determi	nation of Cytotoxicity (Cytopathogenic Reduction Assay)			
1.4.2.2 Influenza Virus  1.4.2.3 Non-Enveloped Viruses  1.4.2.4 Other Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components  1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components  1.7 In Vivo Studies of Essential Oils for its Antiviral Effect  1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  1.7.3 West Nile Virus  2.0 Prof. (Dr.) Sahif Kumar Samanta  M. Pharm., Ph.D (J.U.)  Principal  Dr. B. C. Roy College of Pharmacy & AHS				In Vitro	Activities on Different Viruses			
1.4.2.2 Influenza Virus 1.4.2.3 Non-Enveloped Viruses 1.5 Activities of Essential Oils in Relation to Their Bioactive Components 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 20 Prof. (Dr.) Sanii Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS				1.4.2.1	Human Herpes Virus			
1.4.2.4 Other Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 20 Activities In-Respect to the Available Antivirals  Prof. (Dr.) Santi Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS								
1.4.2.4 Other Viruses  1.5 Activities of Essential Oils in Relation to Their Bioactive Components 1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 20  Prof. (Dr.) Sanif Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS				1.4.2.3	Non-Enveloped Viruses			
1.6 Antiviral Activities as Compared to the Polarity of Bioactive Components 1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 1.7.3 West Nile Virus 20 Activities In-Respect to the Available Antivirals  Prof. (Dr.) Sanif Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS				1.4.2.4	Other Viruses			
1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 20 West Nile Virus 21 Prof. (Dr.) Souli Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS		1.5	Activ	ities of Es	sential Oils in Relation to Their Bioactive Components			
1.7 In Vivo Studies of Essential Oils for its Antiviral Effect 1.7.1 Herpes Simplex Virus 1.7.2 Influenza Virus 20 West Nile Virus 21 Prof. (Dr.) Souli Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS		1.6	Antiv	iral Activ	ities as Compared to the Polarity of Bioactive Components			
1.7.1 Herpes Simplex Virus  1.7.2 Influenza Virus  7.3 West Nile Virus  20  Prof. (Dr.) Sould Kumar Samanta M. Pharm., Ph.D (J.U.)  Principal Dr. B. C. Roy College of Pharmacy & AHS		1.7	In Vi	o Studies	of Essential Oils for its Antiviral Effect			
Prof. (Dr.) Samif Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS	-		171					
Prof. (Dr.) Samif Kumar Samanta M. Pharm., Ph.D (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS	of	Phara	1.7.2	Influenz	za Virus	100		
Prof. (Dr.) Samil Kumar Samanta M. Pharm., Ph.D. (J.U.) Principal Dr. B. C. Roy College of Pharmacy & AHS			<b>— N</b> / <b>¬</b>		le Virus			
Dr. B. C. Roy College of Pharmacy & AHS	Dur	ODA'S	Activ	ities In-R		manta U.)		
					Dr. B. C. Roy College of Pharmac			

				Contents	XV
			Description of the second		
		1.4.4	Foeniculum spp. (Apiaceae)		491
		1.4.5	Coriandrum spp. (Apiaceae)		492
			Pinus spp.		493
	2	1.4.7	GC-O Applied to Characterize Baccharis dracunculifolia		
			DC. Odorants		494
	1	Acknow	vledgements		497
	1	Funding	g		497
		Referen	ices		497
22			n Vivo Methods Used to Assess the Biological Potential		501
		ential C		•	301
	Syed A	li Raza	n Naqvi, Sadaf Ul Hassan, Tauqir A. Sherazi, Amjad Hus	sain,	
			Rehan Hasan Shah Gilani and Tanvir Hussain		501
	22.1	Introdu	uction		502
	22.2	Chemi	stry of EOs		503
	22.3	In Vitre	o Methods Used to Assess the Biological Potential of EOs		504
	22.4	Evalua	tion of Antioxidant Potential		504
		22.4.1	What are Antioxidants?		504
		22.4.2	Antioxidant Potential of Botanical Materials		505
		22.4.3	Modes of Action		505
		22.4.4	In Vitro Methods for Antioxidant Activities		506
		22.4.5	DPPH Scavenging Assay 2,2-Azinobis-(3-Ethylbenzothiazoline-6-Sulfonate) Assa	v	507
			Bleachability of $\beta$ -Carotene in Linoleic Acid System	<b>,</b> ,	510
	22.5	22.4.7	icrobial Activities of Essential Oils		511
	22.5		Disk Diffusion Assay		512
		22.5.1	Agar Well Diffusion Method		512
		22.5.2	Determination of Minimal Inhibitory Concentration (M	IC)	513
	22.6	Fesent	ial Oils as Natural Antimicrobial Agents		514
	22.7		ncer Activity of Essential Oils		515
			ulture and Treatment		515
	22.9		nination of Cell Viability		515
		Conclu			515
			wledgement		515
		Refere			516
23	Biolo	gical Po	otential of Essential Oils: Evaluation Strategies		521
			kraborty, Manami Dhibar, Aliviya Das, <mark>Kalpana Swain</mark>		
	and S	atyana	rayan Pattnaik		
	23.1	Introd			521
	23.2	Biolog	ical Activities of Essential Oils		523
		23.2.1	EOs as Antibacterial Agents		524
011	Paring C	23.2.2	EOs as Antifungal Agents		525
10	13	23.2.3	EOs as Anti-Inflammatory Agents		526
_	but 5	3.2.4	EOs as Antioxidants		526
140	15	3.2.5	EOs as Anticancer Agents  Prof. (Dr.) Samir Kuman M. Pharm., Ph.D	(J.U.)	526
	13/		Principal		
31:1	*/		Dr. B. C. Roy College of Pha Durgapur, West Benga	rmacy & AHS 31-713206	

10 1902 5731 1 1902 514 feature, Described from https://doi.ineliber.cy.wiley.com/des/10 1902/9731 1 1902/974 1 1 1902/974 Oblite Library on [10/97/2023]. See the Terms and Conditions (https://doi.ineliber.cy.wiley.org/

		23.2.6	EOs as Anti-Diabetic Agents	528
		23.2.7	EOs as Antispasmodics	528
	23.3	In Vitro	Assessment of Biological Activities	529
		23.3.1	Antimicrobial Assay	529
		23.3.2		529
		23.3.3	Antifungal Assay	530
		23.3.4		530
		23.3.5		532
				532
	22.4	23.3.6	Anti-Diabetic Assay	532
	23.4		Assessment of Biological Activities	532
		23.4.1	•	533
		23.4.2	* *	533
		23.4.3		533
		23.4.4		534
			Antioxidant Assay	535
			Anticancer Assay	535
		23.4.7		537
			Mosquito Repellent Assay	537
	23.5	Conclu		537
		Referen	nces	331
24	Alga	l Essenti	ial Oils and Their Importance in the Ecosystem	551
		Z. Cobon		
	24.1	Introdu		551
			Essential Oils	552
	24.3	Factors	s Affecting Algae Essential Oil Production	553
	24.5	24.3.1	Temperature	553
		24.3.2		554
			Nutrients	554
			Chemical Stress	554
	24.4	Fcologi	ical Importance of Algal Essential Oils	554
	24.5	Pheron	none Properties of Algal Essential Oils	556
	24.6	Algal E	ssential Oils in "Beach-Odor"	557
	24.7	Algal E	ssential Oils in "Off-Odor"	557
	24.8	Antiba	cterial Activities of Algal Essential Oils	558
	24.9	Antifur	ngal Activities of Algal Essential Oils	558
	24.10			559
	24.10	Referen		559
				565
25			hods for Obtaining Essential Oils	303
	Syed	Raza Ali	Naqvi, Hiba Shahid, Ameer Fawad Zahoor, Muhammad Saeed,	
			Usman, Ali Abbas, Mamoon Ur Rasheed and Tanvir Hussain	F ( F
	251	Introdu		565
0	290	Classica	al Methods for Extracting Essential Oils	568
	1	23, 2.1	Maceration	568
_	apur	Introdu Classica 23.2.1	Prof. (Dr.) Santir Kumar Samanta	
UTS			M. Pharm., Ph.D (J.U.)  Principal	

Dr. B. C. Roy College of Pharmacy & AHS Ourgapur, West Bengal-713206

10 1002 978 (11982 9614 flustres, Developed from https://doi.net/beary.wiley.com/daw/10.10029781119829614 flustres, Wiley Online Library for refer of user, OA strictes are governed by the applicable Centric Common Library of the Common Library wiley confirms and Conditions (https://onlinelibrary.wiley confirms and Conditions) of Wiley Online Library for refer of user, OA strictes are governed by the applicable Centric Common Library of users.